Future Trial Work

Elk OrthoBiologics is planning to a undertake a Phase IIa clinical trial to further assess the safety and efficacy of the CTL102/CB1954 joint repair strategy. Whilst the Phase IIa study will focus on failed hip prostheses, it is envisaged that the therapy will also be applied to other failing joints including knees and shoulders during subsequent trial work. Elk is currently exploring the Orphan Drug potential of the joint repair technology.